US7119076B2 - Preventives or remedies for endometriosis or uterine myoma - Google Patents

Preventives or remedies for endometriosis or uterine myoma Download PDF

Info

Publication number
US7119076B2
US7119076B2 US10/416,802 US41680203A US7119076B2 US 7119076 B2 US7119076 B2 US 7119076B2 US 41680203 A US41680203 A US 41680203A US 7119076 B2 US7119076 B2 US 7119076B2
Authority
US
United States
Prior art keywords
endometriosis
therapy
hysteromyoma
prevention
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/416,802
Other versions
US20040198675A1 (en
Inventor
Masao Sugamata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20040198675A1 publication Critical patent/US20040198675A1/en
Application granted granted Critical
Publication of US7119076B2 publication Critical patent/US7119076B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a drug for prevention and/or therapy of endometriosis and/or hysteromyoma.
  • Endometriosis is a disease wherein endometrium or endometrium-like tissue ectopically proliferates at a site other than the inner surface of the cavity of uterus which is the natural site thereof.
  • the cause of endometriosis is unknown, and therapies such as separation of the adhered tissues by surgery, administration of hormones and administration of analgesics are performed.
  • these therapies are symptomatic treatments, and no complete therapy exists.
  • Hysteromyoma is benign tumor formed on the muscle of uterus, and may cause emmeniopathy and metrorrhagia. If the myoma is large, it compresses ambient organs, so that congestion in the pelvis, lumbago or dragging pain likely to occur. There is no therapy of hysteromyoma other than surgery, and the surgery is total extirpation of uterus in principle. Pharmacotherapy of hysteromyoma is not performed.
  • An object of the present invention is to provide a drug effective for prevention and/or therapy of endometriosis and/or hysteromyoma.
  • the present inventors intensively studied to discover that macrolide antibiotics are effective for prevention and/or therapy of endometriosis and/or hysteromyoma, thereby completing the present invention.
  • the present invention provides a drug for prevention and/or therapy of endometriosis and/or hysteromyoma, comprising a macrolide antibiotic as an effective ingredient.
  • the present invention also provides a use of a macrolide antibiotic for the production of a drug for prevention and/or therapy of endometriosis and/or hysteromyoma.
  • the present invention further provides a method for prevention and/or therapy of endometriosis and/or hysteromyoma, comprising administering a macrolide antibiotic to a patient suffering from endometriosis and/or hysteromyoma, in an amount effective for the prevention and/or therapy of endometriosis and/or hysteromyoma.
  • the present invention a drug effective for prevention and therapy of endometriosis, which can cure endometriosis was first provided.
  • the number of patients suffering from endometriosis is now rapidly increasing, and endometriosis is now one of the main causes of menorrhalgia and infertility.
  • the present invention is thought to greatly contribute in the field of therapy of infertility, and therapy and prevention of menorrhalgia.
  • macrolide antibiotics are effective for prevention and therapy of hysteromyoma of which pathological symptoms are similar to those of endometriosis.
  • the drug for prevention or therapy of endometriosis is effective for both prevention and therapy of endometriosis, and comprises a macrolide antibiotic as an effective ingredient.
  • Macrolide antibiotics means a group of antibiotics having lactone rings (12- to 16-membered lactone ring (the number of atoms constituting the ring is 12 to 16), and having (a) neutral or (an) amino sugar(s).
  • Examples of the macrolide antibiotics which may be employed in the present invention include clarithromycin, roxithromycin, azithromycin, erythromycin, josamycin, leucomycins, spiramycins, carbomycins, tylosin, angolamycin, kitasamycin, acetylspiramycin, midecamycin, oleandomycin, miramycin and maridomycin, as well as hydrates, non-toxic salts and derivatives thereof, although not restricted thereto.
  • derivative herein means those compounds having the same basal skeleton as the original compound, but the substituents attached to the lactone ring and/or sugar(s) are changed, and such derivatives may be used as long as they have antibiotic properties.
  • non-toxic salt include hydrochloric acid salt, sulfuric acid salt, tartaric acid salt and citric acid salt, although the non-toxic salts are not restricted thereto.
  • macrolide antibiotic those having 14-membered or 15-membered lactone ring are preferred, and those in which two sugar units are bound are preferred. Especially, clarithromycin, roxithromycin and azithromycin are preferred.
  • the drug for prevention and/or therapy of endometriosis according to the present invention may be administered by oral administration or parenteral administration such as intravenous, subcutaneous, intramuscular or rectal administration, and oral administration is preferred because it is simple.
  • oral administration is appropriately selected depending on the degree of the symptom of the patient, type of the macrolide antibiotic and the like, the dose is usually about 300 to 500 mg in terms of the amount of the macrolide antibiotic per day per adult.
  • the drug is effective at the dose employed for the therapies of infectious diseases.
  • Adenomyosis of uterus is the state that the endometrium or endometrium-like tissue ectopically proliferates in myometrium, so that it is a form of endometriosis and is included in endometriosis (“Surgical Pathology”, p. 713–715, published by Bunkodo; “Clinical Histopathology”, p.661, published by Kyorin Shoin).
  • the present inventor intensively studied the findings of hysteromyoma. As a result, existence of mast cells and degranulation were observed. Thus, it was confirmed that the findings thereof are the same as the endometriosis from the observation of human cases. Therefore, macrolide antibiotics are effective for the therapy and prevention of hysteromyoma, similarly to endometriosis.
  • the macrolide antibiotic may be granulated together with an additive such as a polyoxyethylenesorbitan fatty acid ester, propylene glycol or sodium laurate, and the resultant may be made into tablets, but the formulation method is not restricted thereto.
  • a drug may be formulated by mixing 50 mg of clarithromycin and 34 mg of polyoxyethylenesorbitan fatty acid ester, granulating the resulting mixture and making tablets from the granulated mixture. Needless to say, the formulation method is not restricted thereto.
  • Endometriosis model rats were prepared by the method described in Michael W. Vernon et al., FERTILITY AND STERILITY, Vol. 44, No. 5, Nov. 1985. That is, endometriosis model rats were prepared as follows: Sprague-Dawley rats (female) of 8 weeks old were acclimatized for 2 weeks under 12 hours light-dark condition. From each rat, right uterine horn was excised under general anesthesia with sevoflurane and ketamine hydrochloride, and a tissue piece sizing 5 mm ⁇ 5 mm was prepared therefrom. The tissue piece was subjected to autotransplantation such that the endometrium surface is attached to peritoneum.
  • Example 2 The same procedures as in Example 1 were repeated except that roxithromycin (trademark “Rulid Tablet 150”, commercially available from Eisai Co., Ltd.) was used in place of clarithromycin.
  • the administration dose was 6 mg/kg per day in terms of roxithromycin.
  • roxithromycin trademark “Rulid Tablet 150”, commercially available from Eisai Co., Ltd.
  • the administration dose was 6 mg/kg per day in terms of roxithromycin.
  • invasion of mast cells and interstitial proliferative lesion were observed.
  • the roxithromycin-administered group invasion of mast cells was not observed, and the degree of interstitial proliferative lesion was apparently reduced.
  • Example 2 The same procedures as in Example 1 were repeated except that azithromycin (trademark “Zithromax Tablet 250 mg”, commercially available from Pfizer Pharmaceuticals Inc.) was used in place of clarithromycin.
  • the administration dose was 10 mg/kg per day in terms of roxithromycin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A drug effective for prevention and therapy of endometriosis and hysteromyoma is disclosed. The drug for prevention and/or therapy of endometriosis and/or hysteromyoma according to the present invention comprises as an effective ingredient a macrolide antibiotic.

Description

This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP01/09972 which has an International filing date of Nov. 15, 2001, which designated the United States of America.
TECHNICAL FIELD
The present invention relates to a drug for prevention and/or therapy of endometriosis and/or hysteromyoma.
BACKGROUND ART
Endometriosis is a disease wherein endometrium or endometrium-like tissue ectopically proliferates at a site other than the inner surface of the cavity of uterus which is the natural site thereof. The cause of endometriosis is unknown, and therapies such as separation of the adhered tissues by surgery, administration of hormones and administration of analgesics are performed. However, these therapies are symptomatic treatments, and no complete therapy exists.
Hysteromyoma is benign tumor formed on the muscle of uterus, and may cause emmeniopathy and metrorrhagia. If the myoma is large, it compresses ambient organs, so that congestion in the pelvis, lumbago or dragging pain likely to occur. There is no therapy of hysteromyoma other than surgery, and the surgery is total extirpation of uterus in principle. Pharmacotherapy of hysteromyoma is not performed.
DISCLOSURE OF THE INVENTION
An object of the present invention is to provide a drug effective for prevention and/or therapy of endometriosis and/or hysteromyoma.
The present inventors intensively studied to discover that macrolide antibiotics are effective for prevention and/or therapy of endometriosis and/or hysteromyoma, thereby completing the present invention.
That is, the present invention provides a drug for prevention and/or therapy of endometriosis and/or hysteromyoma, comprising a macrolide antibiotic as an effective ingredient. The present invention also provides a use of a macrolide antibiotic for the production of a drug for prevention and/or therapy of endometriosis and/or hysteromyoma. The present invention further provides a method for prevention and/or therapy of endometriosis and/or hysteromyoma, comprising administering a macrolide antibiotic to a patient suffering from endometriosis and/or hysteromyoma, in an amount effective for the prevention and/or therapy of endometriosis and/or hysteromyoma.
By the present invention, a drug effective for prevention and therapy of endometriosis, which can cure endometriosis was first provided. The number of patients suffering from endometriosis is now rapidly increasing, and endometriosis is now one of the main causes of menorrhalgia and infertility. Thus, the present invention is thought to greatly contribute in the field of therapy of infertility, and therapy and prevention of menorrhalgia. Further, macrolide antibiotics are effective for prevention and therapy of hysteromyoma of which pathological symptoms are similar to those of endometriosis.
BEST MODE FOR CARRYING OUT THE INVENTION
As mentioned above, the drug for prevention or therapy of endometriosis according to the present invention is effective for both prevention and therapy of endometriosis, and comprises a macrolide antibiotic as an effective ingredient.
Macrolide antibiotics means a group of antibiotics having lactone rings (12- to 16-membered lactone ring (the number of atoms constituting the ring is 12 to 16), and having (a) neutral or (an) amino sugar(s). Examples of the macrolide antibiotics which may be employed in the present invention include clarithromycin, roxithromycin, azithromycin, erythromycin, josamycin, leucomycins, spiramycins, carbomycins, tylosin, angolamycin, kitasamycin, acetylspiramycin, midecamycin, oleandomycin, mirosamycin and maridomycin, as well as hydrates, non-toxic salts and derivatives thereof, although not restricted thereto. The term “derivative” herein means those compounds having the same basal skeleton as the original compound, but the substituents attached to the lactone ring and/or sugar(s) are changed, and such derivatives may be used as long as they have antibiotic properties. Examples of the non-toxic salt include hydrochloric acid salt, sulfuric acid salt, tartaric acid salt and citric acid salt, although the non-toxic salts are not restricted thereto. As the macrolide antibiotic, those having 14-membered or 15-membered lactone ring are preferred, and those in which two sugar units are bound are preferred. Especially, clarithromycin, roxithromycin and azithromycin are preferred.
The drug for prevention and/or therapy of endometriosis according to the present invention may be administered by oral administration or parenteral administration such as intravenous, subcutaneous, intramuscular or rectal administration, and oral administration is preferred because it is simple. Although the administration dose is appropriately selected depending on the degree of the symptom of the patient, type of the macrolide antibiotic and the like, the dose is usually about 300 to 500 mg in terms of the amount of the macrolide antibiotic per day per adult. The drug is effective at the dose employed for the therapies of infectious diseases.
Adenomyosis of uterus is the state that the endometrium or endometrium-like tissue ectopically proliferates in myometrium, so that it is a form of endometriosis and is included in endometriosis (“Surgical Pathology”, p. 713–715, published by Bunkodo; “Clinical Histopathology”, p.661, published by Kyorin Shoin).
The present inventor intensively studied the findings of hysteromyoma. As a result, existence of mast cells and degranulation were observed. Thus, it was confirmed that the findings thereof are the same as the endometriosis from the observation of human cases. Therefore, macrolide antibiotics are effective for the therapy and prevention of hysteromyoma, similarly to endometriosis.
As for the macrolide antibiotics used for the therapy and/or prevention of hysteromyoma, as well as the administration route and administration dose, the above-described explanations for the endometriosis can be applied as they are.
As for the formulation of the drug, any formulation methods ordinarily employed in the field of pharmaceuticals may be employed. For example, the macrolide antibiotic may be granulated together with an additive such as a polyoxyethylenesorbitan fatty acid ester, propylene glycol or sodium laurate, and the resultant may be made into tablets, but the formulation method is not restricted thereto. For example, a drug may be formulated by mixing 50 mg of clarithromycin and 34 mg of polyoxyethylenesorbitan fatty acid ester, granulating the resulting mixture and making tablets from the granulated mixture. Needless to say, the formulation method is not restricted thereto.
Since macrolide antibiotics have been used as therapeutic agents for various infectious diseases, safeties thereof to the extent demanded for pharmaceuticals have been confirmed.
The present invention will now be described more concretely by way of examples. However, the present invention is not limited to the following examples.
EXAMPLE 1 Therapeutic Effect for Endometriosis by Clarithromycin
Endometriosis model rats were prepared by the method described in Michael W. Vernon et al., FERTILITY AND STERILITY, Vol. 44, No. 5, Nov. 1985. That is, endometriosis model rats were prepared as follows: Sprague-Dawley rats (female) of 8 weeks old were acclimatized for 2 weeks under 12 hours light-dark condition. From each rat, right uterine horn was excised under general anesthesia with sevoflurane and ketamine hydrochloride, and a tissue piece sizing 5 mm×5 mm was prepared therefrom. The tissue piece was subjected to autotransplantation such that the endometrium surface is attached to peritoneum.
From 24 hours after the preparation of the endometriosis model rats, commercially available clarithromycin tablets (trademark “Clarith Tablet 50 for Children” prepared by Taisho Pharmaceutical Co., Ltd) were orally administered to the rats for 3 days. The dose of administration was 10 mg/kg per day in terms of clarithromycin. Clarithromycin was not administered to control animals. Seven days after the preparation of the model rats, at which the model lesion reached its peak, the peritoneum tissue including the graft up to the abdominal muscle was excised to obtain a lesion sample. From the thus obtained samples, light microscope specimens (hematoxylin-eosin staining, toluidine blue staining) and electron microscope specimens (uranium-lead double staining) were prepared, and the existence of invaded mast cells, which is a symptom of endometriosis, and the degree of interstitial proliferative lesion were observed.
As a result, in the control group, invasion of mast cells and interstitial proliferative lesion were observed. In contrast, in the clarithromycin-administered group, invasion of mast cells was not observed, and the degree of interstitial proliferative lesion was apparently reduced.
EXAMPLE 2 Therapeutic Effect for Endometriosis by Roxithromycin
The same procedures as in Example 1 were repeated except that roxithromycin (trademark “Rulid Tablet 150”, commercially available from Eisai Co., Ltd.) was used in place of clarithromycin. The administration dose was 6 mg/kg per day in terms of roxithromycin. As a result, in the control group, invasion of mast cells and interstitial proliferative lesion were observed. In contrast, in the roxithromycin-administered group, invasion of mast cells was not observed, and the degree of interstitial proliferative lesion was apparently reduced.
EXAMPLE 3 Therapeutic Effect for Endometriosis by Azithromycin
The same procedures as in Example 1 were repeated except that azithromycin (trademark “Zithromax Tablet 250 mg”, commercially available from Pfizer Pharmaceuticals Inc.) was used in place of clarithromycin. The administration dose was 10 mg/kg per day in terms of roxithromycin. As a result, in the control group, invasion of mast cells and interstitial proliferative lesion were observed. In contrast, in the azithromycin-administered group, invasion of mast cells was not observed, and the degree of interstitial proliferative lesion was apparently reduced.

Claims (3)

1. A method for therapy of endometriosis and/or hysteromyoma, comprising administering a macrolide antibiotic to a patient suffering from endometriosis and/or hysteromyoma, in an amount effective for the therapy of endometriosis and/or hysteromyoma.
2. The method according to claim 1, wherein said macrolide antibiotic is clarithromycin, roxithromycin or azithromycin.
3. The method according to claim 1 or 2, wherein said macrolide antibiotic in an amount effective for the therapy of endometriosis is administered to a patient suffering from endometriosis.
US10/416,802 2000-11-15 2001-11-15 Preventives or remedies for endometriosis or uterine myoma Expired - Fee Related US7119076B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000347643 2000-11-15
PCT/JP2001/009972 WO2002040036A1 (en) 2000-11-15 2001-11-15 Preventives or remedies for endometriosis or uterine myoma

Publications (2)

Publication Number Publication Date
US20040198675A1 US20040198675A1 (en) 2004-10-07
US7119076B2 true US7119076B2 (en) 2006-10-10

Family

ID=18821338

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/416,802 Expired - Fee Related US7119076B2 (en) 2000-11-15 2001-11-15 Preventives or remedies for endometriosis or uterine myoma

Country Status (7)

Country Link
US (1) US7119076B2 (en)
EP (1) EP1344527B1 (en)
JP (1) JP3836790B2 (en)
AT (1) ATE442150T1 (en)
AU (1) AU2002214290A1 (en)
DE (1) DE60139892D1 (en)
WO (1) WO2002040036A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10584370B2 (en) 2014-12-16 2020-03-10 Soft Cell Biological Research, Llc Screening for L-form bacteria
EP3661521A1 (en) * 2017-08-01 2020-06-10 Soft Cell Biological Research, LLC Diagnosis and treatment of endometriosis by screening for l-form bacteria
JPWO2023042714A1 (en) * 2021-09-17 2023-03-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Granovsky-Grisaru et al., Am. J. Obset. Gynecol., vol. 178, No. 1, Part 1, pp. 171-174 (1998).
Mikamo et al., Chermotherapy, vol. 43, pp. 148-152 (1997).
Mikamo et al., Chermotherapy, vol. 44, pp. 50-54 (1998).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions

Also Published As

Publication number Publication date
EP1344527A1 (en) 2003-09-17
DE60139892D1 (en) 2009-10-22
ATE442150T1 (en) 2009-09-15
EP1344527A4 (en) 2008-07-16
JP3836790B2 (en) 2006-10-25
WO2002040036A1 (en) 2002-05-23
JPWO2002040036A1 (en) 2004-03-18
AU2002214290A1 (en) 2002-05-27
EP1344527B1 (en) 2009-09-09
US20040198675A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
US6787342B2 (en) Paste formulations
TWI445537B (en) Method for treating uterine fibroids
US5985877A (en) Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
JP2590358B2 (en) In utero or vaginal administration preparation for endometriosis treatment
ES2281169T3 (en) USE OF AN EXTRACT ENRIQUECIDO IN BIOCANINA FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH STROGENS.
US20090227564A1 (en) Drug for prevention and/or therapy of endometriosis
AU2386301A (en) Fulvestrant formulation
CN103826640A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP2011510949A5 (en)
WO2020177749A1 (en) Chondroitin sulfate polysaccharide, and semi-synthetic preparation method therefor and use thereof
JP2022078298A (en) Multikinase inhibitors and uses in reproductive and digestive tract fibrosis
US7119076B2 (en) Preventives or remedies for endometriosis or uterine myoma
Kaminski et al. Gynecological issues after organ transplantation
JP5314835B2 (en) Preventive or therapeutic agent for endometriosis
JP2018524316A (en) Composition for prevention or treatment of ischemic enteritis comprising DNA fragment mixture isolated from fish semen or testis
CN114533748B (en) Application of pulsatilla chinensis saponin B4 in preparation of medicines for treating or preventing hysteromyoma
EP1641470B1 (en) Vaginal compositions for treating pelvic tissue infections and traumas
Dmowski The role of medical management in the treatment of endometriosis
RU2143238C1 (en) Method of treatment of progressing tubal pregnancy
HU188436B (en) Process for producing suspension veterinary preparation of new composition with antiphlogistic effect
US4857519A (en) Novel pharmaceutical compositions endowed with anti-progesteronic properties and a process for making the same
JP2003526657A (en) Use of CDP-choline for prophylactic treatment of cerebral ischemia
ZANARTU et al. Ovulation induction: Ovarian response to human gonadotropins and synthetic gonadotropin-releasing hormone
Heloury et al. Laparoscopy and intersex
EP2903631B1 (en) Use of degarelix in the treatment of endometriosis and related diseases

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20181010